CN105153299A - lead-IgM chelate as well as preparation method and application thereof - Google Patents
lead-IgM chelate as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN105153299A CN105153299A CN201510412179.6A CN201510412179A CN105153299A CN 105153299 A CN105153299 A CN 105153299A CN 201510412179 A CN201510412179 A CN 201510412179A CN 105153299 A CN105153299 A CN 105153299A
- Authority
- CN
- China
- Prior art keywords
- igm
- lead
- inner complex
- sample
- chromatography column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000013522 chelant Substances 0.000 title abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 104
- 238000001514 detection method Methods 0.000 claims abstract description 26
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 3
- 239000013024 dilution buffer Substances 0.000 claims description 74
- 102000004190 Enzymes Human genes 0.000 claims description 56
- 108090000790 Enzymes Proteins 0.000 claims description 56
- 210000004369 blood Anatomy 0.000 claims description 56
- 239000008280 blood Substances 0.000 claims description 56
- 238000004587 chromatography analysis Methods 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 239000000872 buffer Substances 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 32
- 238000010790 dilution Methods 0.000 claims description 31
- 239000012895 dilution Substances 0.000 claims description 31
- 238000000746 purification Methods 0.000 claims description 31
- 238000001962 electrophoresis Methods 0.000 claims description 29
- 239000003292 glue Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 22
- 238000000502 dialysis Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 230000001900 immune effect Effects 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 14
- 238000000918 plasma mass spectrometry Methods 0.000 claims description 14
- 230000009870 specific binding Effects 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 238000000862 absorption spectrum Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims description 13
- RVPVRDXYQKGNMQ-UHFFFAOYSA-N lead(2+) Chemical compound [Pb+2] RVPVRDXYQKGNMQ-UHFFFAOYSA-N 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 12
- 229920002401 polyacrylamide Polymers 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 238000010612 desalination reaction Methods 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 238000004153 renaturation Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 6
- 239000003547 immunosorbent Substances 0.000 claims description 6
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 238000012797 qualification Methods 0.000 claims description 4
- 238000010170 biological method Methods 0.000 claims description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 5
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000005406 washing Methods 0.000 description 69
- 239000000523 sample Substances 0.000 description 67
- 239000007788 liquid Substances 0.000 description 57
- 229940088598 enzyme Drugs 0.000 description 53
- 239000013642 negative control Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- 238000011534 incubation Methods 0.000 description 15
- 239000012160 loading buffer Substances 0.000 description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 206010027439 Metal poisoning Diseases 0.000 description 8
- 208000008127 lead poisoning Diseases 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 238000005199 ultracentrifugation Methods 0.000 description 7
- -1 washings Substances 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 229910001385 heavy metal Inorganic materials 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 6
- 239000012716 precipitator Substances 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000005469 synchrotron radiation Effects 0.000 description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical group O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- VHJLVAABSRFDPM-IMJSIDKUSA-N L-1,4-dithiothreitol Chemical compound SC[C@H](O)[C@@H](O)CS VHJLVAABSRFDPM-IMJSIDKUSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000673 graphite furnace atomic absorption spectrometry Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DYFFAVRFJWYYQO-UHFFFAOYSA-N n-methyl-n-phenylaniline Chemical group C=1C=CC=CC=1N(C)C1=CC=CC=C1 DYFFAVRFJWYYQO-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000004876 x-ray fluorescence Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a lead-IgM chelate and a preparation method and application thereof, wherein the lead-IgM chelate is formed by chelating lead ions and IgM through sulfydryl or/and cysteine residues. The invention establishes a qualitative and quantitative detection method of a lead-IgM chelate so as to quantitatively detect the application of the lead-IgM chelate in evaluating the lead pollution degree of one region. The lead-IgM chelate in the serum of a regional population can indirectly reflect the lead pollution condition of the regional population by quantitative detection, thereby indirectly reflecting the lead pollution degree of the region. The method for quantitatively detecting the lead-IgM chelate is greatly improved in accuracy and repeatability.
Description
Technical field
The present invention relates to detection field, more particularly, relate to a kind of lead-IgM inner complex and its preparation method and application.
Background technology
In serum, IgM connects into pentamer by 5 monomers by a J chain and disulfide linkage, and molecular weight is maximum, and be 970kD, settling ratio is 19S, is called macroglobulin (macroglobulin).The hingeless sequence of IgM on molecular structure, C μ 2 may instead of the function of hinge area.In organic evolution process, IgM is the immunoglobulin (Ig) occurred the earliest.In ontogenetic process, no matter be B cell Surface Ig (SmIg), or synthesis secretion is all the Ig occurred the earliest to the Ig in serum, IgM, at the fetus i.e. capable generation IgM in fetal development late period.In antigenic stimulation elicit humoral immune answering, general IgM also produces at first.IgM accounts for 5% ~ 10% of serum total Ig.Because IgM produces in early days in immunne response, and hemolytic action under complement participates in is stronger more than 500 times than IgG, and plays opsonization by the fragment such as C3b, C4b after complement activation, and therefore IgM occupies critical role in the early immune protection of body.Natural blood group antibody (lectin) is IgM, the blood transfusion that blood group is not inconsistent, and easily serious hemolytic reaction occurs.IgM can not cross placenta, as there is the IgM for certain pathogenic micro-organism in bleeding of the umbilicus, representing there is corresponding pathogenic micro-organism embryonic stage as infection such as treponema pallidum, rubella or giant cells poison, being called fetal infection or vertical infection.Also containing output monomer I gM in normal human serum.
Plumbous content in vivo exceedes certain level will cause to health the infringement being difficult to recover, it can lead fume, lead dust and various oxide form are taken in body by human body through respiratory tract and digestive tube, by the Competition with calcium ion, oxidative damage, the mechanism such as apoptosis, cause based on nerve, digestion, the general of hemopoietic system obstacle, gradual, persistence non-reversibility disease, and its harm also may be genetic to the next generation.Anaemia is one of saturnine early symptom, and lead can suppress the activity of many enzymes in protoheme building-up process.Lead poisoning can cause vasospasm, angina abdominis, retinal arterioles spasm and hypertension, often causes tiny arteriosclerosis.Plumbous renal impairment often shows as the pathology such as interstitial nephritis or atrophic ephritis, and reabsorption function reduction is early stage symptom.Effects of Lead Exposure also may affect reproductive function, and the probability of the plumbous women's generation Infertility of contact, miscarriage and stillborn foetus increases, and by with it placental metastasis to fetus.Per os lead poisoning person liver is one of main damaged organ, hepatomegaly can be caused to present jaundice, even liver cirrhosis or hepatic necrosis, and hepatic injury may be that in liver, arteriolospasm causes caused by local asphyxia.Lead causes Porphyrin Metabolism obstacle, suppresses containing sulfydryl enzyme, interference vegetative nerve.
Research finds to send out plumbous, and error at measurment is large, and tooth is plumbous, bone is plumbous and organize lead to draw materials not easily, and lead in urine mainly reflects plumbous excretion situation.China's " children's Lead-poisoning and lead poisoning prevention guide " regulation in 2006, the examination of children blood lead levels can adopt peripheral blood or venous blood, but diagnosis must adopt venous blood.But the content affecting the protein binding lead of immunity of organism sphaeroprotein has no precedent detection.
More than comprehensive, about lead poisoning, the particularly evaluation of chronic lead poisoning, only by detecting blood lead content, the circulation lead content in indirect reaction human body, the plumbous degree of injury for body function cannot be assessed further, and along with the develop rapidly of science and technology, plumbous also day by day tight with the relation of human body, thus finding one can become more and more important from the evaluation of body function angle lead poisoning, the particularly chronic lead poisoning evaluation method for the degree of damage of body.
Summary of the invention
For the problem that Lead contamination is serious, the object of the present invention is to provide a kind of lead-IgM inner complex and preparation method thereof, and set up the qualitative and quantitative analysis method of lead-IgM inner complex, so that detection by quantitative lead-IgM inner complex is in the application of an evaluation Pb pollution level.Indirectly can reflect the situation of this regional crowd by Lead contamination by detection by quantitative one regional crowd's Lead in Serum-IgM inner complex, thus indirectly reflect this Pb pollution level.
The technical solution adopted for the present invention to solve the technical problems is: provide a kind of lead-IgM inner complex, lead ion and IgM by sulfydryl or/and cysteine residues chelating forms.
The present invention also provides a kind of preparation method of above-mentioned lead-IgM inner complex, comprises the following steps:
A) chelatropic reaction of lead and IgM: add lead ion and carry out chelatropic reaction in the IgM in people source, obtain reaction soln;
B) extraction of purifying lead-IgM inner complex: adopt immune-affinity chromatography, removes unreacted IgM and unnecessary lead ion in reaction soln, obtains plumbous-IgM inner complex.
Wherein, step B described in external synthesis method) specific as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgM inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgM specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgM and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgM inner complex.
Wherein, the preparation method of above-mentioned lead-IgM inner complex, also comprises step C): to the qualification of lead-IgM inner complex;
Wherein, step C) in specific as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in the lead-IgM inner complex that obtains of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of ICP-MS method, AAS method or ELISA method whether contain plumbous and detect plumbous content.
The present invention also provides the application of a kind of lead-IgM inner complex described above in preparation human body in the reagent of lead-IgM inner complex or test kit.
The present invention also provides a kind of test kit at least comprising lead-IgM inner complex described above product in contrast.
Preferably, also comprise coating buffer in this test kit, this coating buffer contains the albumen can catching IgM or the material of catching metallic lead.
The present invention also provides a kind of method of detection by quantitative lead-IgM inner complex, with the above-mentioned lead-IgM inner complex product in contrast of known content, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification lead-IgM inner complex and enzyme linked immunological combined techniques, purification lead-IgM inner complex and atomic absorption spectrum combined techniques, purification lead-IgM inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.
Implement lead-IgM inner complex of the present invention and its preparation method and application, there is following beneficial effect:
1. the present invention's external synthesis lead-IgM inner complex first;
2. the present invention proposes lead-IgM inner complex first and can be used for preparing application in the reagent or test kit detecting lead-IgM inner complex in blood sample.
3. the present invention establishes the method for qualitative and quantitative detection of lead-IgM inner complex, so that detection by quantitative lead-IgM inner complex is in the application of an evaluation Pb pollution level.Indirectly can reflect the situation of this regional crowd by Lead contamination by detection by quantitative one regional crowd's Lead in Serum-IgM inner complex, thus indirectly reflect this Pb pollution level.Its accuracy of lead-IgM inner complex quantitative detecting method that the present invention sets up improves greatly, and the repeatability of detection is greatly enhanced.
Accompanying drawing explanation
Fig. 1 is the non denatured electrophoretic band figure of lead-IgM inner complex of the present invention;
Fig. 2 is the fluorometric analysis figure of the synchrotron radiation X line electrophoretic band of lead-IgM inner complex of the present invention;
Wherein, in Fig. 1, M is Marker, and 2 is lead-IgM inner complex; In Fig. 2, X-coordinate is protein band position, and ordinate zou is lead metal energy in this protein band.
Embodiment
Below, in conjunction with embodiment, the present invention is described further:
Unless otherwise indicated, the laboratory operating procedures related to is the step of this area routine in the present invention, and agents useful for same, material are as cited by following, and the reagent being this area conventional not enumerating out in the present invention maybe can be obtained by commercial mode:
Extracting reagent is PEG solution, borate buffer solution etc. (adopting PEG method);
Glue bed medium is the one in sepharose, polyacrylamide gel;
In the present invention described can with the filler of IgM specific binding, for surface is with the silica gel of albumen or the resin that can catch IgM;
The albumen (anti-IgM) catching IgM in the present invention, include but not limited to rabbit Anti-mankind IgMH & L, its brand is Abcam, model is ab8505;
In the present invention can with the filler of plumbous specific binding, for surface is with silica gel or the resin that can catch plumbous material;
Plumbous material can be caught in the present invention, include but not limited to mouse-anti PbmAb, buy from Ba Ao moral biotech company (BioWorldInc), article No. be AP7019;
Enzyme labelled antibody is the one in the antibody containing the enzyme labelling such as horseradish peroxidase, alkaline phosphatase;
Substrate is methyl diphenyl amine (TMB) solution;
Washings is for containing KH
2pO
40.2mg/ml, Na
2hPO
412H
2the pH of O2.90mg/ml, NaCl8.0mg/ml, KCl0.2mg/ml, 0.5%Tween-20 is the 0.15MPBS solution of 7.4;
Confining liquid is 1%-5% bovine serum albumin or skim-milk;
Dilution buffer is for containing 1.5mg/mLNa
2cO
3, 2.93mg/mlNaHCO
3pH be 9.6 0.05M phosphate buffered saline buffer;
Enzyme labelled antibody is HRP enzyme labelled antibody;
Stop buffer is: by the 2MH of 21.7ml
2sO
4be settled to the ddH of 200ml
2in O;
Elutriant be containing the PH of 1-2mg/ml papoid be 8.0 0.1mol/LTris-HCL damping fluid;
Souring agent is nitric acid;
Sample-loading buffer is for containing 1MTris-HCl (pH6.8) 15.5mL, 1% tetrabromophenol sulfonphthalein 2.5mL, ddH
2the Samplebuffer (5X) of O7mL, glycine 25mL;
Electrophoretic buffer be containing Tris3mg/ml, glycine 14.4mg/ml PH be the ddH of 6.8
2o solution.
The present invention also provides a kind of preparation method of lead-IgM inner complex, comprises the following steps:
A) the plumbous chelatropic reaction with IgM: add lead ion in the IgM in people source or the IgM that recombinates according to biological method and carry out chelatropic reaction, obtain reaction soln;
B) extraction of purifying lead-IgM inner complex: adopt immune-affinity chromatography, remove unreacted IgM and unnecessary lead ion in reaction soln, obtain plumbous-IgM inner complex, concrete steps are as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgM inner complex is redissolved
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgM specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgM and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgM inner complex;
C) to the qualification of lead-IgM inner complex, concrete steps are as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in the lead-IgM inner complex that obtains of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of ICP-MS method, AAS method or ELISA method whether contain plumbous and detect plumbous content.
The present invention also provides a kind of test kit at least comprising lead-IgM inner complex described above product in contrast.
Preferably, also comprise coating buffer in this test kit, this coating buffer contains the material that the albumen can catching IgM maybe can catch metallic lead.
In the present invention, the test kit that can realize the object of the invention can be listed following several, but is not limited to this.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: containing catching the coating buffer of albumen of IgM, confining liquid, washings, material, enzyme labelled antibody, substrate, stop buffer, dilution buffer, sample-loading buffer, positive control, negative control etc. as two anti-caught lead.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: the coating buffer, confining liquid, washings, elutriant, sample-loading buffer, positive control, negative control etc. that contain the albumen can catching IgM.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: the coating buffer, confining liquid, washings, elutriant, sample-loading buffer, souring agent, hydrogen peroxide, standard substance, negative control etc. that contain the albumen can catching IgM.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: as extracting reagent, redissolution liquid in purification whole blood needed for IgM, containing the coating buffer, confining liquid, washings, enzyme labelled antibody, substrate, stop buffer, dilution buffer, sample-loading buffer, positive control, negative control etc. that can catch plumbous material.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: as extracting reagent, redissolution liquid, sample-loading buffer, positive control, negative control etc. in purification whole blood needed for IgM.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: extract reagent, sample-loading buffer, redissolution liquid, souring agent, hydrogen peroxide, positive control, negative control etc. needed for IgM as in purification whole blood.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: contain liquid needed for protein band leaded on the coating buffer of the albumen can catching IgM, glue bed medium, redissolution liquid, sample-loading buffer, dissolving glue bed, containing the coating buffer, confining liquid, washings, enzyme labelled antibody, substrate, stop buffer, dilution buffer, positive control, negative control etc. that can catch plumbous material.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: as extracting liquid, positive control, negative control etc. needed for protein band leaded on reagent, glue bed medium, redissolution liquid, sample-loading buffer, dissolving glue bed in purification whole blood needed for IgM.
Detect a test kit for lead-IgM inner complex in blood sample, comprising: as extracting liquid, souring agent, hydrogen peroxide, positive control, negative control etc. needed for protein band leaded on reagent, glue bed medium, redissolution liquid, sample-loading buffer, dissolving glue bed in purification whole blood needed for IgM.
In above-mentioned several test kit, described positive control is standard substance, is namely chelated with the IgM inner complex of heavy metal lead or is chelated with the BSA inner complex of heavy metal lead; Described negative control is dilution buffer.
Mentioned reagent box is for detecting the IgM of chelating lead, to improve the accuracy of detection, repeated, and makes it to be promoted in clinical.
The present invention also provides a kind of method of detection by quantitative lead-IgM inner complex, with the above-mentioned lead-IgM inner complex product in contrast of known content, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification lead-IgM inner complex and enzyme linked immunological combined techniques, purification lead-IgM inner complex and atomic absorption spectrum combined techniques, purification lead-IgM inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.In the present invention, following several with having of detecting that the method for plumbous chelating type immunocomplex can list, but be not limited to following several.
Wherein, the reagent adopted in the method for above-mentioned detection by quantitative lead-IgM inner complex is as follows:
method one:euzymelinked immunosorbent assay (ELISA) (ELISA method) detects lead-IgM inner complex, detects in accordance with the following steps:
1) material of IgM can be caught, as human IgM antibody is coated on solid phase carrier: dilute anti-IgMAb to 500-4000 doubly by dilution buffer, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgM inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) material can catching lead is added, and incubation: remove measuring samples, and wash with washings, after washing completes, add with dilution buffer dilution and plumbous material can be caught or can react with lead the anti-pbAb forming immune complex, 37 DEG C of effect 1-2 hour, make the metallic lead on anti-pbAb and IgM react;
6) enzyme conjugates incubation: remove anti-antibody lead, and wash with washings, after washing completes, add the enzyme labelled antibody with dilution buffer dilution, make the concentration of the enzyme labelled antibody of dilution be 2 μ g/ml, 37 DEG C of effect 1-2 hour, make itself and enzyme labelled antibody react;
7) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
8) termination reaction: drip stop buffer to each micropore;
9) wavelength 405nm is got, after adding stop buffer, elisa plate is placed at OD value microplate reader reading respectively measuring samples and standard substance, by drawing standard curve, try to achieve the content (also microplate reader can not be used, directly carry out qualitative detection by staining conditions) of measuring samples.
The method utilizes ELISA principle, specific IgM in whole blood can be extracted, the IgM upper part extracted is chelated with heavy metal lead, and lead on this part IgM can catch by the specific antibody of anti-lead, afterwards can again by horseradish peroxidase, the antibody of the enzyme labellings such as alkaline phosphatase is caught (this antibody nonrecognition coating protein), the antibody of catching is under the effect of developer and stop buffer, OD value can be read under instrument, and the IgM not containing chelated mineral lead, then can not catch by the specific antibody of anti-lead, also can not with horseradish peroxidase, the antibody of the enzyme labellings such as alkaline phosphatase caught, and also not containing metallic lead (negative control group result is negative) in agents useful for same, thus when read OD value result is shown as the positive, the i.e. provable metallic lead detecting chelating on IgM.
method two:enzyme linked immunological and atomic absorption spectrum combined techniques (ELISA method+AAS method) detect lead-IgM inner complex and detect in accordance with the following steps:
1) material of IgM can be caught, as human IgM antibody is coated on solid phase carrier: dilute anti-IgMAb to 500-4000 doubly by dilution buffer, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, the centrifugal 5-8 minute of 1000rpm, centrifugally discard precipitation;
3) close: remove coating buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgM inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, with elution 1-3 hour.
6) detect: sample from ELISA micropore, detect the lead of chelating on IgM in Atomic Absorption Spectroscopy AAS, and drawing standard curve, read respective value;
In conjunction with atomic absorption spectrum (AAS) principle on the basis that this embodiment utilizes ELISA principle, Atomic Absorption Spectroscopy AAS is utilized to detect the lead of chelating on IgM, owing to only containing IgM in solution, and not containing any heavy metal (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, i.e. the provable metallic lead detecting chelating on IgM.
method three:enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques (ELISA method+ICP-MS method) detect lead-IgM inner complex and detect in accordance with the following steps:
1) material of IgM can be caught, as human IgM antibody is coated on solid phase carrier: dilute anti-IgMAb to 500-4000 doubly by dilution buffer, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgM inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, with elution 1-3 hour.
6) acidifying: in step 5) in solution in add respective acids agent acidifying carried out to solution, sealing is spent the night, thorough acidifying;
7) detect: add hydrogen peroxide, and acid is caught up with in heating, and from ELISA agent plate wash-out solution in sample, under icp ms, detect chelating in the lead of IgM, and drawing standard curve, read respective value.
The method is on the basis utilizing ELISA principle, in conjunction with sense coupled plasma mass spectrometry (ICP-MS) principle, the lead of chelating on IgM is detected with icp ms, owing to only containing IgM in solution, and not containing any heavy metal (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, i.e. the provable metallic lead detecting chelating on IgM.
method four:purification lead-IgM inner complex and enzyme linked immunological combined techniques (method of purification+ELISA method) detect lead-IgM inner complex, detect in accordance with the following steps:
1) from whole blood, IgM is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to adopt whole blood extraction method to be redissolved by the purification of blood IgM out, obtain the redissolution liquid of IgM;
2) anti-pbAb is coated on solid phase carrier: dilute anti-pbAb to 50000-400000 doubly by dilution buffer, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) measuring samples is added, and incubation: sample from the redissolution liquid of the IgM extracted, make measuring samples; Standard substance are made with the lead-IgM inner complex of known content; Dilute corresponding multiple by dilution buffer, namely dilute 10-40 doubly, add in micropore, 37 DEG C of effect 1-2 hour;
5) enzyme conjugates incubation: the redissolution liquid removing IgM, and wash with washings, after washing completes, add the enzyme labelled antibody with dilution buffer dilution, make the concentration of the enzyme labelled antibody of dilution be 2 μ g/ml, 37 DEG C of effect 1-2 hour, make itself and enzyme labelled antibody react;
6) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
7) termination reaction: drip stop buffer to each micropore;
8) wavelength 405nm is got, after adding stop buffer, elisa plate is placed at OD value microplate reader reading respectively measuring samples and standard substance, by drawing standard curve, try to achieve the content (also microplate reader can not be used, directly carry out qualitative detection by staining conditions) of measuring samples.
method five:purification lead-IgM inner complex and atomic absorption spectrum combined techniques (method of purification+AAS method) detect lead-IgM inner complex in blood sample, detect in accordance with the following steps:
1) from whole blood, IgM is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgM out from whole blood extraction method, obtain the redissolution liquid of IgM;
2) detect: from step 1) redissolution liquid in sample, detect the lead of chelating on IgM in Atomic Absorption Spectroscopy AAS, and drawing standard curve, read respective value.
method six:purification lead-IgM inner complex and inductivity coupled plasma mass spectrometry combined techniques (method of purification+ICP-MS method) detect lead-IgM inner complex, detect in accordance with the following steps:
1) from whole blood, IgM is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgM out from whole blood extraction method, obtain the redissolution liquid of IgM;
2) acidifying: from step 1) redissolution liquid in sample, add respective acids agent (as nitric acid) in the solution and carry out acidifying to solution, sealing is spent the night, thorough acidifying;
3) detect: add hydrogen peroxide, and acid is caught up with in heating, and sample from corresponding solution, under icp ms, detect the lead of chelating on IgM, and drawing standard curve, read respective value.
method seven:electrophoresis and euzymelinked immunosorbent assay (ELISA) (electrophoretic method-ELISA method) detect lead-IgM inner complex, detect in accordance with the following steps:
1) from whole blood, IgM is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgM out from whole blood extraction method, obtain the redissolution liquid of IgM;
2) glue bed is prepared: select sepharose or polyacrylamide gel or SDS-polyacrylamide gel etc. as medium as required, conventionally prepare corresponding glue bed;
3) application of sample: get step 1) in redissolution liquid 8 μ L add 2 μ L sample-loading buffers, mixing, of short duration centrifugal; (noticing that step can not be boiled herein)
4) electrophoresis: connect electrophoresis plate, carry out electrophoretic separation;
5) detect: find out on glue bed containing plumbous protein band, this band is taken out, this protein band is redissolved, and then utilize ELISA principle to detect the lead content be dissolved in liquid.In addition, the iso-electric point of the IgM of this method detection chelating lead, molecular weight and content etc. can also be utilized.
method eight:electrophoresis and atomic absorption spectrometry (electrophoretic method-AAS method) detect lead-IgM inner complex, detect in accordance with the following steps:
1) from whole blood, IgM is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgM out from whole blood extraction method, obtain the redissolution liquid of IgM;
2) glue bed is prepared: select sepharose or polyacrylamide gel or SDS-polyacrylamide gel etc. as medium as required, prepare glue bed;
3) application of sample: from step 1) redissolution liquid in sample, add sample-loading buffer, and mix, then application of sample is in sample cell;
4) electrophoresis: connect electrophoresis plate, carry out electrophoretic separation;
5) detect: find out on glue bed containing plumbous protein band, this band is taken out, this protein band is redissolved, and then utilize AAS principle to detect the lead content be dissolved in liquid.In addition, the iso-electric point of the IgM of this method detection chelating lead, molecular weight and content etc. can also be utilized.
method nine:inductivity coupled plasma mass spectrometry combined techniques (electrophoretic method-ICP-MS method) detects lead-IgM inner complex, detects in accordance with the following steps:
1) from whole blood, IgM is extracted: adopt the method such as the polyoxyethylene glycol PEG precipitator method, ultracentrifugation, molecule ultrafiltration, gel-filtration to be redissolved by the purification of blood IgM out from whole blood extraction method, obtain the redissolution liquid of IgM;
2) glue bed is prepared: select sepharose or polyacrylamide gel or SDS-polyacrylamide gel etc. as medium as required, prepare glue bed;
3) application of sample: from step 1) redissolution liquid in sample, add sample-loading buffer, and mix, then application of sample is in sample cell;
4) electrophoresis: connect electrophoresis plate, carry out electrophoretic separation;
5) detect: find out on glue bed containing plumbous protein band, this band is taken out, this protein band is redissolved, and then utilize ICP-MS principle to detect the lead content be dissolved in liquid.In addition, the iso-electric point of the IgM of this method detection chelating lead, molecular weight and content etc. can also be utilized.
IgM in method seven to nine can by multiple Methods For Purification out (such as ultracentrifugation, HPLC, gel-filtration chromatography, gel electrophoresis, ELISA method etc.), the IgM purified out is redissolved, obtain the redissolution liquid of IgM, get a certain amount of IgM, utilize electric charge shifting principle, carry out electrophoresis (electrophoresis, EP), can according to molecular weight on gel slab (different media can be adopted as required), the difference such as iso-electric point runs out of different bands, find out and be rich in plumbous respective strap, the corresponding double solvents of protein in gel is redissolved in solution, namely the content of relevant IgM can be detected at a particular wavelength, also ELISA can be utilized, AAS, the principles such as ICP-MS detect the lead content of chelating on IgM, owing to only containing IgM in solution, and not containing any heavy metal (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, the i.e. provable metallic lead detecting chelating on IgM.
embodiment 1: the preparation method of lead-IgM inner complex, comprises the following steps:
A) chelatropic reaction of lead and IgM: add lead ion and carry out chelatropic reaction in the IgM in people source, obtain reaction soln;
Preparation of reagents:
1) borate buffer solution (0.01M): take 0.31g boric acid and be dissolved in 400ml ultrapure water, regulates pH to 9.0 with the NaOH of 0.1M, is settled to 500mL.
2) IgM solution: take 4.0mgIgM and be dissolved in 4.0mL0.01MpH9.0 borate buffer solution, dissolving of fully vibrating, is mixed with the protein solution of 1.0mg/mL;
3) 5mmol/LEDTA+200mmol/LNaHCO
3solution: take EDTA2H
2o1.86g, NaHCO
316.8g is dissolved in 900mL ultrapure water, adjusts pH to 8.0 be settled to 1000ml, autoclaving, room temperature preservation with 1.0MNaOH;
4) ITCBE (buying from Japanese colleague's chemistry institute, article No. M030)
5) dialysis tubing (molecular weight cut-off 14000) (BioshopInc)
Preparation process is specially:
1) process of dialysis tubing: 5mmol/LEDTA+200mmol/LNaHCO dialysis tubing being put into 500ml (according to the convertible consumption of beaker volume) volume
3in solution, boil 10min; Tipping EDTA/NaHCO
3liquid, with ultrapure water rinsing gently, then boils 10min with 500ml5mmol/LEDTA; Discard boiling liquid, thoroughly with ultrapure water cleaning, add a large amount of ultrapure water immersion dialysis tubings 4 DEG C and spend the night.During use, put on one's gloves, take out dialysis tubing, with a large amount of its surfaces externally and internallies of ultrapure water cleaning down;
2) getting 2.0mgITCBE is dissolved in 2mlDMSO;
3) getting 4.0mgIgM to be dissolved in 4.0ml borate buffer solution in (0.01MpH9.0);
4) liquid slowly step 2 prepared adds in IgM solution, and dropping limit, limit is shaken, and in 25 DEG C, acts on 24h in the shaking table of 100r/min, then to dialyse 24h with dialysis tubing, removes the ITCBE be not combined with IgM;
5) by the liquid 1mol/LHCl adjust ph to 7.0 of dialysis gained, then slowly drip 80 μ l1mmol/L lead ion solution gradually, dropping limit, limit vibrates, in order to avoid lead ion makes protein denaturation precipitate;
6) by the solution that added at 25 DEG C, react 2h in the shaking table of 100r/min, carry out dialysis 24h with the dialysis tubing handled well;
7) liquid after dialysis is preserved in-20 DEG C of packing.
B) extraction of purifying lead-IgM inner complex: adopt immune-affinity chromatography, remove the liquid after the dialysis of reaction soln (namely in steps A 7)) in unreacted IgM and unnecessary lead ion, obtain plumbous-IgM inner complex, concrete steps are as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgM inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgM specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgM and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgM inner complex;
C) to the qualification of lead-IgM inner complex, concrete steps are as follows:
(1) glue bed is prepared: prepare glue bed using sepharose as medium;
(2) application of sample: get step B) in the lead-IgM inner complex that obtains of 8 μ L extraction purification, add 2 μ L sample-loading buffers, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, add electrophoretic buffer and carry out electrophoresis; In electrophoresis process, electric current is 22mA constant current, and envrionment temperature is 4 degree; Electrophoresis is stopped when moving to bottom glue to tetrabromophenol sulfonphthalein;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of AAS method whether contain plumbous and detect plumbous content.
D) detected result
(1) electrophoresis result:
Wherein, Fig. 1 is the non denatured electrophoretic band figure of lead-IgG inner complex of the present invention.
(2) Synchrotron Radiation X-Ray Fluorescence Anal ysis:
In protein band, the SRXRF of micronutrient levels analyzes and " synchrotron radiation bunch completes at the 4W1 of Beijing electron positron collider (BEPC).In storage ring, beam current energy is 2.2GeV, beam intensity 100mA.Sample transfer table (TSA200 type, Beijing stand upright Han Guang company) can move up to change launching spot position along X, Y two-dimensional square under computer-controlled step motor drives, and moving step length is 0.0025mm.The X-ray gone out from electromagnetic radiation is detected by Si (Li) detector (PGTInc.LS30143-DS), probe is mutually vertical with incident SR line copline, apart from sample irradiation point 20mm, signal obtains with PGT MCA (MCA4000) and exports.By the monochromatic synchrotron radiation light excited sample of 11.5keV, launching spot (1mmx3mm) position is regulated to make it to be in band one end, in the minute of 300s, hot spot is always along band evenly slowly movement, and at the end of counting, hot spot moves on to this band the other end.A spectrum is got along the every 1mm in electrophoresis direction.Adopt AXIL software data processing, and with deriving from air and the Ar fignal center of content constant carries out normalization to other element peak, to offset the impact that beam intensity change produces signal power.Measure the fluorescence Spectra of the dry glued membrane of quantitative criterion at identical conditions in the same way.
Fig. 2 is the fluorometric analysis figure of the synchrotron radiation X line electrophoretic band of lead-IgM inner complex of the present invention, and in figure, X-coordinate is protein band position, and ordinate zou is lead metal energy (content) value in this protein band.
(3) lead content in the lead-IgG inner complex adopting graphite furnace atomic absorption spectrometry (AAS) rough determination the present embodiment to obtain, its content is 591.339 μ g/L.
the determination of the testing conditions of the method for a kind of detection by quantitative lead of the present invention-IgM inner complex:
1. the determination of the optimum diluting multiple of complement proteins best effort concentration and blood plasma
Step is as follows:
(1) anti-IgMAb dilution buffer is diluted according to following mass volume ratio (extent of dilution) 1:500,1:1000,1:2000,1:4000, add in elisa plate micropore, be coated on solid phase carrier by anti-IgMAb, each concentration bag is by three rows, and 4 DEG C are spent the night 18 hours;
(2) remove dilution buffer, and wash with washings, after washing completes, with 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C;
(3) measuring samples dilution buffer is diluted according to following mass volume ratio (extent of dilution) 1:10,1:20,1:40, add in micropore, according to the anti-IgMAb concentration of above-mentioned bag quilt, the anti-IgMbAb of same concentration adds different extent of dilution blood plasma respectively, 37 DEG C of effects 1 hour;
(4) measuring samples is removed, and wash with washings, after washing completes, add anti-pbAb, anti-pbAb dilution buffer is diluted according to following mass volume ratio (extent of dilution) 1:50000,1:100000,1:200000,1:400000, and according to each identical anti-IgMAb, serum-dilution concentration, the anti-pbAb of different concns respectively adds 2 holes, 37 DEG C act on 1 hour, the metallic lead on anti-pbAb and IgM are reacted;
(5) enzyme labelled antibody selects the suitableeest working concentration, i.e. 2ng/ml, removes anti-pb antibody, and wash with washings, after washing completes, add with dilution buffer dilution HRP enzyme labelled antibody, 37 DEG C act on 1 hour, HRP enzyme labelled antibody and lead-IgM inner complex are reacted;
(6) remove enzyme labelled antibody, and wash with washings, after washing completes, add substrate, 37 DEG C of lucifuge effects 30 minutes;
(7) stop buffer is dripped to each micropore;
(8) get wavelength 405nm, after adding stop buffer, elisa plate is placed in microplate reader and reads each hole OD value respectively.According to each hole OD value numerical value, select the best effort concentration of anti-IgMAb, anti-pb-Ab and the optimum diluting multiple of blood plasma.
Simultaneously using made reference substance as positive control in test, IgM antibody+closed+pb is selected to resist+enzyme mark+substrate (namely do not add and detect sample) as negative control 1, IgM antibody+close+blood plasma+enzyme mark+substrate (namely not adding pb to resist) as negative control 2, IgM antibody+close+enzyme mark+substrate (namely do not add detect sample and pb resist) is as negative control 3, IgM antibody+close+blood plasma+pb is anti-+ and substrate (i.e. not enzyme-added mark) is as negative control 4, close+blood plasma+pb is anti-+ and enzyme mark+substrate (namely not adding IgM antibody) is as blank 1, only add substrate and PBS as blank 2, detected result is in Table 1-2.
Table 1: the determination of anti-IgMAb and pb antibody best effort concentration and diluted plasma multiple
Table 2:ELISA positive control and negative control ELISA detected result
By table 1-2 data presentation, when we can find out that the extent of dilution when human IgM antibody is 1:1000, whole blood extent of dilution be the anti-extent of dilution of 1:10, pb is 1:50000, OD value is maximum, although OD value is less than 0.8, but the negative control group OD value corresponding to it is all less than 0.1, and the positive controls corresponding to it, OD value is greater than 0.8, so select the concentration corresponding to this value, as best effort concentration, (namely human IgM antibody concentration is 1:1000, whole blood extent of dilution is the anti-weaker concn of 1:10, pb is 1:50000).
2.ELISA elutriant best effort concentration and time are determined
Step is as follows: human IgM antibody dilution buffer is diluted to 1000 times (mass volume ratios) by (1), adds in elisa plate micropore, 37 DEG C of water-baths 3 hours, stores refrigerator;
(2) remove dilution buffer, and wash with washings, after washing completes, with 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C;
(3) remove confining liquid, and wash with washings, after washing completes, add the HRP enzyme labelled antibody with dilution buffer dilution, 37 DEG C act on 2 hours, itself and human IgM antibody are reacted;
(4) prepare elutriant: papoid pH8.0,0.1mol/LTris-HCI buffer is become 1-2mg/ml, then add 1mmol/L dithiothreitol (DTT) (DTT) 37 DEG C and hatch 30min;
(5) enzyme labelled antibody is removed, by dilution buffer, elutriant is diluted, make the Papain enzyme concn in elutriant: enzyme labelled antibody concentration ratio=1:80,1:40,1:20,1:10,1:5, wherein, each concentration does 3 multiple holes, is positioned over wash-out 1h, 2h, 3h at 37 DEG C of temperature respectively;
(6) remove elutriant, and wash with washings, after washing completes, add substrate, 37 DEG C of lucifuge effects 30 minutes;
(7) stop buffer is dripped to each micropore;
(8) get 405nm wavelength, after adding stop buffer, be placed at by elisa plate in microplate reader and read often group OD value respectively, by comparing with PBS damping fluid group, compare optimal concentration and the elution time of elutriant, concrete outcome is see table 3.
Table 3:ELISA elutriant best effort concentration and elution time are determined
| 1:5 | 1:10 | 1:20 | 1:40 | 1:80 | |
| 1h | 0.281 | 0.168 | 0.081 | 0.114 | 0.469 |
| 2h | 0.250 | 0.115 | 0.050 | 0.183 | 0.438 |
| 3h | 0.225 | 0.106 | 0.100 | 0.196 | 0.441 |
From table 4, we can find, during ratio=the 1:20 of the concentration of the papoid in elutriant with the concentration of enzyme labelled antibody, during the concentration 100ng/ml of i.e. papoid, each group of OD value is all lower than other several groups, this concentration elution effect optimum (reach maximum by the human IgM antibody that ELISA hole wall combines-enzyme mark mixture wash-out degree, thus OD value is minimum) is described; And no matter action time is 1h, 2h, 3h, the change of each group OD value is all little, as seen along with the prolongation of time, enzyme activity weakens gradually, when enzyme concn is constant, extend digestion time can not improve digestibility, so in this experiment the action time of elutriant be that 1-3h all can.
application Example 1
Get and adopt ELISA method to detect lead-IgM inner complex in 100 parts of sample blood plasma, detect according to following steps: euzymelinked immunosorbent assay (ELISA) (ELISA method) detects lead-IgM inner complex, detect in accordance with the following steps:
1) anti-IgMAb is coated on solid phase carrier: dilute anti-IgMAb to 1000 times by dilution buffer, adds in elisa plate micropore, 37 DEG C of water-baths 1 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, then add toluene, dissolved cell film;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgM inner complex of known content; Be diluted to corresponding multiple with dilution buffer dilution measuring samples, namely dilute 10 times, add in micropore, 37 DEG C act on 1 hour;
5) material can catching lead is added, and incubation: remove measuring samples, and wash with washings, after washing completes, add and dilute 50000 times by dilution buffer, 37 DEG C act on 1 hour, the metallic lead on anti-pbAb and IgM are reacted;
6) enzyme conjugates incubation: remove anti-antibody lead, and wash with washings, after washing completes, adds the HRP enzyme labelled antibody with dilution buffer dilution, and 37 DEG C act on 1 hour, itself and enzyme labelled antibody are reacted;
7) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
8) termination reaction: drip stop buffer to each micropore;
9) wavelength 405nm is got, after adding stop buffer, elisa plate is placed at the OD value (also can not use microplate reader, directly carry out qualitative detection by staining conditions) microplate reader reading respectively measuring samples and standard substance, detected result is as shown in table 4.
The ELISA detected result of lead-IgM inner complex in table 4:100 part blood sample
| Numbering | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| OD 405 | 0.440 | 0.658 | 0.4 | 0.575 | 0.348 | 0.781 | 0.593 | 0.348 | 0.691 | 0.272 |
| Numbering | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| OD 405 | 0.405 | 0.638 | 0.542 | 0.615 | 0.338 | 0.411 | 0.279 | 0.558 | 0.749 | 0.625 |
| Numbering | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| OD 405 | 0.413 | 0.110 | 0.320 | 0.650 | 0.672 | 0.271 | 0.649 | 0.384 | 0.353 | 0.506 |
| Numbering | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 |
| OD 405 | 0.582 | 0.123 | 0.642 | 0.292 | 0.463 | 0.642 | 0.145 | 0.588 | 0.561 | 0.733 |
| Numbering | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
| OD 405 | 0.715 | 0.471 | 0.796 | 0.485 | 0.309 | 0.455 | 0.704 | 0.381 | 0.683 | 0.479 |
| Numbering | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 |
| OD 405 | 0.800 | 0.292 | 0.584 | 0.650 | 0.363 | 0.182 | 0.243 | 0.326 | 0.706 | 0.764 |
| Numbering | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 |
| OD 405 | 0.465 | 0.384 | 0.68 | 0.529 | 0.337 | 0.354 | 0.262 | 0.759 | 0.355 | 0.399 |
| Numbering | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 |
| OD 405 | 0.201 | 0.516 | 0.449 | 0.457 | 0.794 | 0.721 | 0.325 | 0.199 | 0.692 | 0.584 |
| Numbering | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 |
| OD 405 | 0.346 | 0.581 | 0.533 | 0.598 | 0.773 | 0.604 | 0.538 | 0.447 | 0.472 | 0.552 |
| Numbering | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 |
| OD 405 | 0.566 | 0.558 | 0.791 | 0.353 | 0.435 | 0.328 | 0.700 | 0.362 | 0.330 | 0.355 |
application Example 2
Employing enzyme linked immunological and atomic absorption spectrum combined techniques (ELISA method+AAS method) detect the lead-IgM inner complex in 100 points of sample blood samples, detect in accordance with the following steps:
1) can catch the material of IgM, as anti-IgM (anti-IgMAb) is coated on solid phase carrier: dilute anti-IgMAb to 1000 times by dilution buffer, add in elisa plate micropore, 4 DEG C are spent the night 18 hours;
2) get whole blood from the recycle system, make measuring samples, then add toluene, dissolved cell film;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgM inner complex of known content; Be diluted to 10 times with dilution buffer dilution measuring samples, add in micropore, 37 DEG C act on 1 hour;
5) wash-out: remove measuring samples, and washing with washings, after washing completes, the elutriant that to add with the concentration of papoid be 100ng/ml, wash-out 3 hours;
6) detect: sample from ELISA micropore, detect the lead of chelating on IgM in Atomic Absorption Spectroscopy AAS, detected value is as shown in table 5.
The AAS detected result of lead-IgM inner complex in table 5:100 part blood sample
| Numbering | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| μg/L | 2.271 | 2.22 | 3.324 | 3.071 | 3.154 | 3.247 | 3.231 | 1.686 | 2.903 | 2.227 |
| Numbering | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| μg/L | 2.426 | 3.241 | 3.656 | 1.986 | 3.473 | 2.786 | 2.54 | 3.047 | 1.081 | 2.533 |
| Numbering | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| μg/L | 2.076 | 3.188 | 3.156 | 3.039 | 2.853 | 2.545 | 2.874 | 2.49 | 3.334 | 1.063 |
| Numbering | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 |
| μg/L | 4.000 | 1.407 | 2.207 | 2.944 | 2.23 | 2.465 | 3.431 | 2.234 | 1.951 | 2.929 |
| Numbering | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
| μg/L | 3.378 | 2.363 | 1.979 | 3.407 | 2.568 | 1.184 | 4.509 | 4.488 | 3.500 | 2.701 |
| Numbering | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 |
| μg/L | 1.666 | 2.614 | 3.138 | 3.074 | 3.024 | 2.815 | 1.381 | 2.449 | 2.918 | 2.483 |
| Numbering | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 |
| μg/L | 2.275 | 3.051 | 3.371 | 3.282 | 2.132 | 3.479 | 2.816 | 1.981 | 3.01 | 2.544 |
| Numbering | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 |
| μg/L | 1.916 | 1.972 | 3.098 | 1.949 | 3.468 | 2.941 | 2.211 | 3.399 | 1.381 | 1.958 |
| Numbering | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 |
| μg/L | 3.155 | 1.959 | 2.84 | 3.036 | 2.092 | 3.282 | 2.43 | 2.658 | 2.681 | 1.081 |
| Numbering | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 |
| μg/L | 2.680 | 2.838 | 2.433 | 2.702 | 2.092 | 3.025 | 3.446 | 3.396 | 3.374 | 3.643 |
application Example 3
Employing enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques (ELISA method+ICP-MS method) detect the lead-IgM chelate content in 100 points of sample blood samples, detect in accordance with the following steps:
1) can catch the material of IgM, as anti-IgM (anti-IgMAb) is coated on solid phase carrier: dilute anti-IgMAb to 1000 times by dilution buffer, add in elisa plate micropore, 4 DEG C are spent the night 18 hours;
2) get 100 parts of standard blood samples as measuring samples, then add toluene, dissolved cell film;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the lead-IgM inner complex of known content; Be diluted to 10 times with dilution buffer dilution measuring samples, add in micropore, 37 DEG C act on 1 hour;
5) wash-out: remove measuring samples, and washing with washings, after washing completes, the elutriant that to add with the concentration of papoid be 100ng/ml, wash-out 3 hours;
6) acidifying: in step 5) in solution in add nitric acid acidifying carried out to solution, sealing is spent the night, thorough acidifying;
7) detect: add hydrogen peroxide, and acid is caught up with in heating, and sample from corresponding solution, under icp ms, detect chelating in the lead of IgM, detected value is as shown in table 6.
The ICP-MS detected result of table 6100 part sample blood sample lead-IgM inner complex
| Numbering | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| μg/L | 3.268 | 2.713 | 2.029 | 2.556 | 2.198 | 1.954 | 2.879 | 2.12 | 1.941 | 4.060 |
| Numbering | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| μg/L | 3.378 | 2.423 | 2.656 | 3.210 | 2.309 | 2.366 | 1.987 | 3.174 | 4.073 | 2.901 |
| Numbering | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| μg/L | 2.218 | 3.068 | 2.669 | 3.454 | 2.11 | 3.328 | 2.094 | 2.087 | 2.210 | 1.960 |
| Numbering | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 |
| μg/L | 2.158 | 2.764 | 1.784 | 4.499 | 4.468 | 2.258 | 2.163 | 1.339 | 3.165 | 3.440 |
| Numbering | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
| μg/L | 2.43 | 2.632 | 2.337 | 1.981 | 2.859 | 3.377 | 3.065 | 2.537 | 2.083 | 2.243 |
| Numbering | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 |
| μg/L | 2.841 | 2.214 | 3.034 | 3.145 | 1.181 | 2.779 | 1.946 | 3.111 | 2.382 | 3.084 |
| Numbering | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 |
| μg/L | 3.412 | 1.908 | 3.334 | 2.962 | 3.289 | 4.440 | 1.913 | 3.222 | 2.608 | 3.100 |
| Numbering | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 |
| μg/L | 2.898 | 2.103 | 2.039 | 3.186 | 1.736 | 2.629 | 3.327 | 2.655 | 3.141 | 3.158 |
| Numbering | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 |
| μg/L | 3.41 | 2.935 | 2.121 | 2.588 | 3.341 | 1.454 | 2.415 | 2.433 | 3.261 | 2.24 |
| Numbering | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 |
| μg/L | 3.326 | 2.666 | 2.734 | 3.119 | 3.116 | 2.887 | 3.200 | 1.959 | 3.105 | 3.323 |
To one skilled in the art, according to technical scheme described above and design, other various corresponding change and deformation can be made, and all these change and deformation all should belong within the protection domain of the claims in the present invention.
Claims (8)
1. a lead-IgM inner complex, is characterized in that, lead ion and IgM by sulfydryl or/and cysteine residues chelating forms.
2. a preparation method for lead-IgM inner complex as claimed in claim 1, is characterized in that, comprise the following steps:
A) the plumbous chelatropic reaction with IgM: people source IgM or the IgM that recombinates according to biological method in add lead ion and carry out chelatropic reaction, obtain reaction soln;
B) extraction of purifying lead-IgM inner complex: adopt immune-affinity chromatography, removes unreacted IgM and unnecessary lead ion in reaction soln, obtains plumbous-IgM inner complex.
3. preparation method according to claim 2, is characterized in that,
Described step B) specific as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains, lead-IgM inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of IgM specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), IgM and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out;
(5) collect: collect the elutriant after step (4) wash-out, after collection, make protein renaturation immediately;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of plumbous specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out;
(10) collect: collect the elutriant after step (9) wash-out, after collection, make protein renaturation immediately;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain plumbous-IgM inner complex.
4. the preparation method of lead-IgM inner complex according to claim 2, is characterized in that, also comprise step C): to the qualification of lead-IgM inner complex;
Wherein, step C) in specific as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in the lead-IgM inner complex that obtains of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out leaded protein band, this protein band is taken out, protein band is redissolved, and then adopt the detection of ICP-MS method, AAS method or ELISA method whether contain plumbous and detect plumbous content.
5. the application of lead-IgM inner complex as claimed in claim 1 in the reagent or test kit preparing to detect lead-IgM inner complex in blood sample.
6. one kind at least comprises the test kit of lead-IgM inner complex as claimed in claim 1 as standard substance.
7. test kit according to claim 6, is characterized in that, also comprises coating buffer, and this coating buffer contains the material that the albumen can catching IgM maybe can catch metallic lead.
8. the method for a detection by quantitative lead-IgM inner complex, it is characterized in that, using the lead-IgM inner complex according to claim 1 of known content as standard substance, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification lead-IgM inner complex and enzyme linked immunological combined techniques, purification lead-IgM inner complex and atomic absorption spectrum combined techniques, purification lead-IgM inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510412179.6A CN105153299A (en) | 2015-07-14 | 2015-07-14 | lead-IgM chelate as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510412179.6A CN105153299A (en) | 2015-07-14 | 2015-07-14 | lead-IgM chelate as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105153299A true CN105153299A (en) | 2015-12-16 |
Family
ID=54794380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510412179.6A Pending CN105153299A (en) | 2015-07-14 | 2015-07-14 | lead-IgM chelate as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105153299A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022490A1 (en) * | 1993-03-29 | 1994-10-13 | Immunomedics, Inc. | Conjugates of proteins and bifunctional ligands |
| CN101422621A (en) * | 2007-10-31 | 2009-05-06 | 韩国科学技术研究院 | Method for the production of bio-imaging nanoparticles with high yield by early introduction of irregular structure |
-
2015
- 2015-07-14 CN CN201510412179.6A patent/CN105153299A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022490A1 (en) * | 1993-03-29 | 1994-10-13 | Immunomedics, Inc. | Conjugates of proteins and bifunctional ligands |
| CN101422621A (en) * | 2007-10-31 | 2009-05-06 | 韩国科学技术研究院 | Method for the production of bio-imaging nanoparticles with high yield by early introduction of irregular structure |
Non-Patent Citations (2)
| Title |
|---|
| 刘功良等: "铅螯合物人工抗原的制备与鉴定", 《生物技术通报》 * |
| 胡向阳等: "《环境污染健康损害因果关系鉴定研究》", 31 January 2015 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105137059B (en) | Mercury chelating immune complex and preparation method and application thereof | |
| CN104987409A (en) | Lead-IgG chelate as well as preparation method and application thereof | |
| CN105153299A (en) | lead-IgM chelate as well as preparation method and application thereof | |
| CN105021548B (en) | Arsenic-fibrinogen chelate as well as preparation method and application thereof | |
| CN104987412A (en) | Arsenic-IgE chelate as well as preparation method and application thereof | |
| CN104987411A (en) | Cadmium-IgA chelate as well as preparation method and application thereof | |
| CN105044004B (en) | Mercury-IgM chelate as well as preparation method and application thereof | |
| CN104987414A (en) | Nickel-IgM chelate as well as preparation method and application thereof | |
| CN104961824A (en) | Lead and high-density lipoprotein chelate as well as preparation method and application thereof | |
| CN104987400A (en) | Mercury-hemoglobin chelate as well as preparation method and application thereof | |
| CN104987415A (en) | Chromium-IgM chelate as well as preparation method and application thereof | |
| CN104987410A (en) | Lead-IgE chelate as well as preparation method and application thereof | |
| CN104987407A (en) | Cadmium-IgG chelate as well as preparation method and application thereof | |
| CN105037537A (en) | lead-IgA chelate as well as preparation method and application thereof | |
| CN105021554B (en) | arsenic-IgM chelate as well as preparation method and application thereof | |
| CN105044006B (en) | Mercury-IgG chelate and preparation method and application thereof | |
| CN105044007A (en) | cadmium-IgM chelate as well as preparation method and application thereof | |
| CN105004684A (en) | Nickel-IgE chelate as well as preparation method and application thereof | |
| CN105001310B (en) | Chromium-chelated immune complex and preparation method and application thereof | |
| CN105001321A (en) | Mercury-fibrinogen chelate and preparation method and application thereof | |
| CN105017430B (en) | Nickel chelate immune complex and preparation method and application thereof | |
| CN104987404A (en) | Nickel-IgG chelate as well as preparation method and application thereof | |
| CN104987386A (en) | Lead-fibrinogen chelate as well as preparation method and application thereof | |
| CN105115914B (en) | Cadmium-low density lipoprotein chelate as well as preparation method and application thereof | |
| CN104987405A (en) | Arsenic-IgG chelate as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151216 |
|
| RJ01 | Rejection of invention patent application after publication |